New User:

Forgot your password?

Stock Market & Financial Investment News

Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
August 3, 2015
07:47 EDTTSNTyson Foods sees FY16 revenue approximately $41B, consensus $41.84B
Subscribe for More Information
07:46 EDTTSNTyson Foods reports Q3 chicken segment revenue $2.76B vs. $2.83B last year
Reports Q3 beef segment revenue $4.31B vs. $4.19B last year. Reports Q3 pork segment revenue $1.21B vs. $1.77B last year. Reports Q3 prepared foods segment revenue $1.81B vs. $901M last year. Reports Q3 international segment revenue $244M vs. $365M last year.
07:45 EDTTSNTyson Foods reports Q3 adjusted EPS 80c, consensus 92c
Subscribe for More Information
07:40 EDTTSNTyson Foods lowers FY15 EPS view to $3.10-$3.20 from $3.30-$3.40
Subscribe for More Information
06:51 EDTNFLXIcahn made approach for Relativity Media takeover, NY Post reports
Activist investor Carl Icahn has made an approach to Relativity CEO Ryan Kavanaugh before the company filed for bankruptcy last Thursday, the New York Post reports, citing sources. Icahn most recently was a major stakeholder in Netflix, and "Tinseltown spies" wonder whether Netflix's Reed hastings will be among investors eyeing the studio, the report says. Reference Link
06:49 volatility elevated into Q2 and outlook
Subscribe for More Information
06:30 EDTVVUSVIVUS price target lowered to $2.30 from $3 at WallachBeth
WallachBeth analyst Bob Ai lowered his price target for VIVUS for $2.30 after the company announced plans to cut its sales force by one-half, to 50, in order to achieve its new corporate goal of operating cash flow being neutral or positive by the end of 2016. This is not the best move for long-term shareholders, Ai tells investors in a research note. The sales force reduction may result in a significant sales decline, the analyst believes. He keeps a Hold rating on VIVUS.
July 31, 2015
16:22 EDTMRKStocks end week higher in U.S. despite selloff in China
Subscribe for More Information
14:07 EDTMCKLeerink healthcare tech analyst holds analyst/industry conference call
Subscribe for More Information
13:19 EDTMRKNewLink Ebola results promising, says Mizuho
Subscribe for More Information
12:25 EDTCTRPExpedia hits 52-week high after Q2 profit tops estimates
Shares of online travel company Expedia (EXPE) are rising after the company’s second quarter adjusted profit topped analysts’ consensus estimates and it reported strong gross bookings. WHAT'S NEW: After the close on Thursday, Expedia reported Q2 adjusted earnings per share of 89c, topping analysts' consensus estimates of 84c, on revenue of $1.66B, in line with the consensus projection. The company reported adjusted EPS, excluding eLong (LONG), of $1.02. WHAT'S NOTABLE: Expedia reported Q2 room night growth, excluding eLong, grew to 35% year-over-year, with domestic and international room nights growing 24% and 50%, respectively. It reported gross bookings and revenue, excluding eLong, increased 20% and 15%, respectively. Excluding the impact of foreign exchange, gross bookings increased 28%. In Q2, Expedia added nearly 27,000 properties to its global supply portfolio, which now stands at approximately 257,000. ANALYST REACTION: RBC Capital said this morning that Expedia's results were "surprisingly strong," given intra-quarter comments by the company. The firm raised its price target on the name to $140 from $130 and kept an Outperform rating on the shares. PRICE ACTION: In early afternoon trading, Expedia rose $11, or about 10%, to $118.65 on more than twice its average daily trading volume. Earlier in the session, the stock made a fresh 52-week high of $119. Including today’s advance, the shares have gained approximately 50% over the past year. OTHERS TO WATCH: Other online travel companies include Priceline Group (PCLN), which is up 2.3%, Travelzoo (TZOO), which is up 0.6%, (CTRP), which is up 1.8% and Orbitz Worldwide (OWW) and Tripadvisor (TRIP), whose shares are flat.
11:34 EDTNFLXStocks with call strike movement; FEYE NFLX
Subscribe for More Information
09:02 EDTMCKCintas to acquire ZEE Medical from McKesson for approx. $130M in cash
Subscribe for More Information
08:24 EDTMRKNewLink Genetics announces data suggesting efficacy of Ebola vaccine
NewLink Genetics (NLNK) announced that the international partnership studying the VSV-ZEBOV Ebola vaccine candidate in Guinea has released interim data suggesting that it is effective against Ebola in a large clinical trial. Interim results suggest that the vaccine candidate demonstrates efficacy within about 10 days of administration to a person without the infection. The VSV-ZEBOV Ebola vaccine candidate was originally developed by the Public Health Agency of Canada, and was subsequently licensed to a subsidiary of NewLink Genetics. In late 2014, Merck (MRK) licensed the vaccine from NewLink Genetics to apply Merck’s vaccine expertise to help accelerate the development of this promising candidate. Merck is now responsible for research, development and manufacturing of the rVSV-ZEBOV vaccine.
08:13 EDTMRKMerck: Investigational ebola vaccine had 100% efficacy in study analysis
Subscribe for More Information
07:31 EDTALKSAlkermes reported solid Q2 financial results, says Leerink
Leerink analyst Michael Schmidt says Alkermes reported solid Q2 financial results driven by stronger than expected Vivitrol sales. All pipeline programs remain on track, Schmidt tells investors in a post-earnings research note. He reiterates an Outperform rating on the stock with a $79 price target.
05:44 EDTNFLXRovi price target lowered to $23 from $27 at JPMorgan
JPMorgan analyst Sterling Auty lowered his price target for Rovi (ROVI) to $23 saying the company's Q2 results and guidance were worse than expected. The Netflix (NFLX) litigation outcome has led to slower sales cycles, Auty tells investors in a research note. He sees an uncertain growth outlook going forward and keeps a Neutral rating on Rovi.
July 30, 2015
19:08 EDTVVUSVIVUS announces restructuring plan, will reduce headcount
Subscribe for More Information
16:22 EDTNFLXRovi to continue pursuing Netflix litigation
Rovi (ROVI) said in its earnings release, "While we are disappointed with the Netflix ruling, we continue to believe in our broader IP licensing business. Our second half focus is on achieving our sales and profit objectives, continuing our big-four renewal negotiations, securing meaningful design wins for our products and continuing to pursue our Netflix litigation."
16:02 EDTVVUSVIVUS reports Q2 EPS (19c), consensus (24c)
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use